Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001193125-25-283076
Filing Date
2025-11-14
Accepted
2025-11-14 16:25:35
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 11322
  Complete submission text file 0001193125-25-283076.txt   13169
Mailing Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451
Business Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451 617-945-5576
Cogent Biosciences, Inc. (Subject) CIK: 0001622229 (see all company filings)

EIN.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90431 | Film No.: 251486880
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 245 LYTTON AVE., SUITE 350 PALO ALTO CA
Business Address 245 LYTTON AVE., SUITE 350 PALO ALTO CA 650-924-9424
TCG Crossover GP I, LLC (Filed by) CIK: 0001839947 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A